#treatmentoption — Public Fediverse posts

GSK Canada and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Blenrep for the treatment of relapsed or refractory multiple myeloma

MISSISSAUGA, ON, Sept. 22, 2026 /CNW/ — GSK Canada announced today that it has completed negotiations with the…
#EuropeSays #Britain #Europe #EU #GSK #adultpatients #Blenrep #bloodcancer #Canada #eligiblepatients #multiplemyeloma #refractory #treatmentoption #treatmentoptions
https://www.europesays.com/britain/129232/

https://www.europesays.com/britain/129232/ GSK Canada and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Blenrep for the treatment of relapsed or refractory multiple myeloma #AdultPatients #Blenrep #BloodCancer #Canada #EligiblePatients #GSK #MultipleMyeloma #refractory #TreatmentOption #TreatmentOptions

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Approval Addresses High Unmet Medical Need and Further Advances Viatris’ Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026…
#EuropeSays #Japan #JP #controlledsubstance #excessivedaytimesleepiness #globalhealthcarecompany #narcolepsy #OSAS #patients #treatmentoption #Viatris #WAKIX
https://www.europesays.com/japan/92567/

GILD Stock Garners Retail Attention On Trodelvy EU Approval Ahead Of August 27 HIV FDA Verdict

Expanding Trodelvy into the first-line setting strengthens Gilead’s oncology franchise, which has been growing alongside its dominant HIV…
#Europe #EU #EuropeanUnion #FDA #gildstock #Gilead #GileadSciences #HIV #treatmentoption #Trodelvy
https://www.europesays.com/europe/122796/

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO, August 24, 2026–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European …
#Europe #EU #ACADIAPharmaceuticals #DAYBU #EuropeanCommission #EuropeanUnion #neurodevelopmentaldisorder #pediatricpatients #raredisease #Rettsyndrome #treatmentoption #treatmentoptions
https://www.europesays.com/europe/122619/

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNB…
#Europe #EU #adultpatients #breastcancer #EuropeanUnion #GileadSciences #metastaticbreastcancer #metastaticdisease #systemictherapy #treatmentoption #treatmentoptions #Trodelvy #unresectable
https://www.europesays.com/europe/122410/

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) …
#NewsBeep #News #Medication #Ecopipam #foodanddrugadministration #Health #JAMANeurology #NDA #OrphanDrugDesignation #pediatricpatients #teva-pharmaceuticals #TouretteSyndrome #treatmentoption #treatmentoptions #UK #UnitedKingdom
https://www.newsbeep.com/uk/743230/

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) is a …
#NewsBeep #News #Medication #AU #Australia #Ecopipam #foodanddrugadministration #Health #JAMANeurology #NDA #OrphanDrugDesignation #pediatricpatients #tevapharmaceuticals #tourettesyndrome #treatmentoption #treatmentoptions
https://www.newsbeep.com/au/861088/

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) is a …
#NewsBeep #News #Medication #AU #Australia #Ecopipam #foodanddrugadministration #Health #JAMANeurology #NDA #OrphanDrugDesignation #pediatricpatients #tevapharmaceuticals #tourettesyndrome #treatmentoption #treatmentoptions
https://www.newsbeep.com/au/861088/

https://www.europesays.com/ch/97555/ Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) #EuropeanApproval #EuropeanCommission #EuropeanUnion #GeneReplacementTherapy #GeneTherapy #MotorFunction #MotorNeuron #Novartis #SpinalMuscularAtrophy #TreatmentOption #TreatmentOptions

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
#Europe #EU #EuropeanCommission #Europeanapproval #EuropeanUnion #genereplacementtherapy #genetherapy #motorfunction #motorneuron #Novartis #spinalmuscularatrophy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/86554/

https://www.europesays.com/ch/95770/ Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) #EuropeanApproval #EuropeanCommission #EuropeanUnion #GeneReplacementTherapy #GeneTherapy #MotorFunction #MotorNeuron #Novartis #SpinalMuscularAtrophy #TreatmentOption #TreatmentOptions

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
#Europe #EU #EuropeanCommission #Europeanapproval #EuropeanUnion #genereplacementtherapy #genetherapy #motorfunction #motorneuron #Novartis #spinalmuscularatrophy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/84390/

https://www.europesays.com/ch/82319/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #AdultPatients #CholinergicUrticaria #ChronicHives #ChronicSpontaneousUrticaria #ColdUrticaria #EAACI #Novartis #TreatmentOption #TreatmentOptions #urticaria

https://www.europesays.com/ch/82297/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #AdultPatients #CholinergicUrticaria #ChronicHives #ChronicSpontaneousUrticaria #ColdUrticaria #EAACI #Novartis #TreatmentOption #TreatmentOptions #urticaria

https://www.europesays.com/britain/50544/ GSK’s Blenrep Gets Chinese Regulatory Nod Amid Doubling of Multiple Myeloma Incidence #AdultPatients #Blenrep #China #dexamethasone #GSK #MultipleMyeloma #NationalMedicalProductsAdministration #ReceivedApproval #TreatmentOption

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Ipsen Pharma New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals…
#Europe #EU #EuropeanCommission #BRAF #pediatricbraintumors #PediatricNeuro-Oncology #systemictherapy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/19691/

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Ipsen Pharma New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals…
#Europe #EU #EuropeanCommission #BRAF #pediatricbraintumors #PediatricNeuro-Oncology #systemictherapy #treatmentoption #treatmentoptions
https://www.europesays.com/europe/19682/

https://www.europesays.com/ch/32987/ Novartis wins FDA approval for Cosentyx to treat paediatric HS patients #Cosentyx #Cosentyx dosing #FoodAndDrugAdministration #Novartis #paediatric patients #TreatmentOption

https://www.europesays.com/ch/32969/ Novartis wins FDA approval for Cosentyx to treat paediatric HS patients #Cosentyx #FoodAndDrugAdministration #Novartis #paediatric patients #TreatmentOption

https://www.europesays.com/ch/32580/ Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa #Cosentyx #FDA #HidradenitisSuppurativa #Novartis #pediatric patients #PsoriaticArthritis #TreatmentOption #TreatmentOptions

https://www.europesays.com/ch/31642/ Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa #Cosentyx #FDA #HidradenitisSuppurativa #Novartis #pediatric patients #PsoriaticArthritis #TreatmentOption #TreatmentOptions

https://www.alojapan.com/1418105/glyconex-and-hokkaido-university-hospital-launch-study-to-advance-glycan-directed-adc-development-in-gastric-cancer-2/ GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer #BiotechnologyCompany #ClinicalDevelopment #ClinicalStage #GastricCancer #GlycoNex #Hokkaido #HokkaidoNews #HokkaidoUniversity #Inc. #Japan #news #TreatmentOption #TreatmentOptions #北海道 Collaboration builds clinical foundation for GNX1021, a first-in-class glycan-directed ADC being developed for gastric cancer patients  NEW TAIP

https://www.alojapan.com/1418105/glyconex-and-hokkaido-university-hospital-launch-study-to-advance-glycan-directed-adc-development-in-gastric-cancer-2/ GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer #BiotechnologyCompany #ClinicalDevelopment #ClinicalStage #GastricCancer #GlycoNex #Hokkaido #HokkaidoNews #HokkaidoUniversity #Inc. #Japan #news #TreatmentOption #TreatmentOptions #北海道 Collaboration builds clinical foundation for GNX1021, a first-in-class glycan-directed ADC being developed for gastric cancer patients  NEW TAIP

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive famil…
#Japan #JP #JapanNews #bileacid #Ipsen #liverfailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #pruritussymptoms #regulatoryapproval #treatmentoption
https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive famil…
#Japan #JP #JapanNews #bileacid #Ipsen #liverfailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #pruritussymptoms #regulatoryapproval #treatmentoption
https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/

https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/ Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC #BileAcid #Ipsen #Japan #JapanNews #LiverFailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #PruritusSymptoms #RegulatoryApproval #TreatmentOption Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offe

https://www.alojapan.com/1373348/bylvay-odevixibat-approved-in-japan-for-rare-liver-disease-pfic/ Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC #BileAcid #Ipsen #Japan #JapanNews #LiverFailure #news #odevixibat #PFIC #ProgressiveFamilialIntrahepaticCholestasis #PruritusSymptoms #RegulatoryApproval #TreatmentOption Ipsen Pharma Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offe

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Pharmaceutical Industries Ltd FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migrai…
#NewsBeep #News #Medication #adolescentpatients #Adolescents #AJOVY #AU #Australia #FDA #Health #Migraine #pediatricpatients #Prevention #preventivetreatment #Teva #treatmentoption
https://www.newsbeep.com/au/48093/

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Pharmaceutical Industries Ltd FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventi…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #adolescentpatients #adolescents #AJOVY #FDA #Health #migraine #pediatricpatients #prevention #preventivetreatment #Teva #treatmentoption
https://www.newsbeep.com/us/62828/

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Pharmaceutical Industries Ltd FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventi…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #adolescentpatients #adolescents #AJOVY #FDA #Health #migraine #pediatricpatients #prevention #preventivetreatment #Teva #treatmentoption
https://www.newsbeep.com/us/62828/

https://www.europesays.com/uk/322752/ FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine #AdolescentPatients #adolescents #AJOVY #FDA #Health #Medication #migraine #PediatricPatients #Prevention #PreventiveTreatment #Teva #TreatmentOption #UK #UnitedKingdom

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Pharmaceutical Industries Ltd FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic mi…
#NewsBeep #News #Medication #adolescentpatients #adolescents #AJOVY #FDA #Health #migraine #pediatricpatients #prevention #preventivetreatment #Teva #treatmentoption #UK #UnitedKingdom
https://www.newsbeep.com/uk/47997/